| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.8 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Inflammatory bowel disease includes Crohn's disease and ulcerative colitis. Chronic inflammatory disease of the gastrointestinal (GI) tract is characterized by recurrent ulceration. IBD affects 7–10% of people worldwide, mainly of Caucasian descent. It manifests into several intestinal and extra-intestinal symptoms, mainly related to oxidative stress, inflammation, and autoimmune reaction. Aim of the study: evaluate the influence of a new pharmacological approach with erythropoietin in the establishment and development of inflammation associated with IBD, through of an experimental colitis model in rodents.
Description
IDI&CA_COLITIS/2019
Keywords
Inflammatory bowel disease Ulcerative colitis Crohn disease Erythropoietin Animal model IDI&CA_COLITIS/2019
Citation
Silva IJ, Pinto R, Mateus V. New pharmacological approach for inflammatory bowel disease. In: 3rd World Congress on Pharmacology & Toxicology, Crowne Plaza London – Heathrow, West Drayton (UK), September 12-14, 2019.